-

Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Award (GEWA), marking the third consecutive year the company has received this prestigious recognition. The award honors organizations with some of the most engaged workplace cultures in the world.

Gallup recognized Exact Sciences for fostering a culture where employees feel valued and connected to the company’s mission, enabling strong performance even during periods of change and complexity.

"Our people are the heart of Exact Sciences,” said Sarah Condella, executive vice president of human resources. “This recognition belongs to them. Every day, our team shows up with purpose, supports one another, and stays focused on advancing the fight against cancer. We will keep raising the bar for ourselves and for the patients who count on us.”

Gallup’s research shows that organizations that prioritize engagement and performance are better positioned for long-term success. Its meta-analysis, based on data from more than 3.3 million employees across 347 organizations in 53 industries and 90 countries, found that highly engaged organizations outperform peers in areas including customer ratings, profitability, productivity, retention, safety, quality and overall wellbeing.

For a complete list of GEWA winners, visit the 2026 Gallup Exceptional Workplace Award Winners page. Learn more about the awards here.

Exact Sciences is looking for talented people who are passionate about helping patients and fighting cancer. For more information and to view a complete list of job openings, visit the company’s careers site.

About Exact Sciences

A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company’s growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like Cancerguard® for blood-based analysis of molecular information across multiple cancers and Oncodetect® for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com, follow @ExactSciences on X, or connect on LinkedIn and Facebook.

About Gallup

Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining more than 80 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students and citizens than any other organization in the world.

Contacts

Media Contacts

Exact Sciences
Blair Brophy
bbrophy@exactsciences.com
608-630-7391

Exact Sciences Corp.

NASDAQ:EXAS

Release Versions

Contacts

Media Contacts

Exact Sciences
Blair Brophy
bbrophy@exactsciences.com
608-630-7391

More News From Exact Sciences Corp.

Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze tri...

Exact Sciences Stockholders Approve Acquisition by Abbott

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie...

Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $878 million for the fourth quarter of 2025 and $3.25 billion for the full year of 2025, both ended December 31, 2025. “In 2025 the Exact Sciences team delivered on our mission by screening more people than ever before, helping guide more personalized treatment decisions, and successfully launching three new tests...
Back to Newsroom